Blueberries Medical (BBM) AI Stock Analysis

• Market Cap: C$9.90M
• Dividend Yield: N/A
• Average Volume (3M): 5.83K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.13
• Revenue Growth: 52.39%
• EPS Growth: 5.13%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 495,090,100
• 10 Day Avg. Volume: 10,565
• 30 Day Avg. Volume: 5,826
• PEG Ratio: 0.06
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 8.46
• P/FCF Ratio: -5.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.07
• Revenue Forecast (FY): C$74.47M

• Rating: 52 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by the company's financial performance challenges, including ongoing losses and cash flow issues. While technical analysis suggests a positive trend, the negative valuation metrics due to lack of profitability weigh heavily on the score.

Blueberries Medical Business Overview & Revenue Model

Company Description

Blueberries Medical (BBM) is a healthcare company focused on developing and providing innovative medical solutions, primarily in the field of cannabinoid-based therapies. Operating within the medical cannabis sector, BBM is dedicated to improving patient outcomes through research, cultivation, and the formulation of high-quality cannabinoid products. The company is involved in various aspects of the medical supply chain, including the production of pharmaceutical-grade cannabis extracts and the distribution of these products to licensed healthcare providers and patients.

How the Company Makes Money

Blueberries Medical generates revenue through multiple key streams. Primarily, the company earns income from the sale of its proprietary cannabinoid-based products to licensed healthcare providers and patients, capitalizing on the growing demand for alternative therapies in the medical cannabis market. Additionally, BBM has established partnerships with research institutions and healthcare organizations, allowing it to collaborate on clinical trials and product development, which can lead to further monetization opportunities. The company may also explore licensing agreements for its formulations or intellectual property, contributing to its overall revenue. Furthermore, BBM's investment in cultivation facilities enables it to control production costs and enhance profit margins, while also allowing for potential expansion into new markets.

Blueberries Medical Financial Statement Overview

Summary

Blueberries Medical faces substantial challenges in achieving profitability and positive cash flow. While revenue growth offers a positive sign, the company struggles with operational efficiency and cash generation. The balance sheet remains relatively stable with low leverage, but persistent losses and cash flow issues pose significant risks to financial stability.

Income Statement

Blueberries Medical has shown some progress in revenue growth but continues to face significant profitability challenges. The gross profit margin has fluctuated but remains low, indicating efficiency issues. The net profit margin is negative, highlighting ongoing losses. Despite revenue growth, the EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position, although it has faced declining total assets over recent years. The debt-to-equity ratio is low, suggesting conservative leverage use. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is healthy, showing good asset financing through equity.

Cash Flow

Cash flow analysis reveals significant negative operating cash flow and free cash flow, reflecting ongoing cash burn issues. The free cash flow to net income ratio is concerning, as it indicates inefficiencies in converting net income into cash. The operating cash flow to net income ratio is negative, showing issues in operational cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	439.33K	471.41K	288.27K	235.45K	138.75K	65.98K
Gross Profit	176.51K	164.52K	84.22K	-17.72K	-245.45K	62.40K
EBITDA	-1.42M	-1.04M	-1.22M	-811.47K	-4.05M	-4.11M
Net Income	-1.54M	-1.15M	-1.64M	-1.47M	-5.15M	-4.94M
Balance Sheet
Total Assets	1.34M	1.38M	2.42M	3.35M	3.59M	7.27M
Cash, Cash Equivalents and Short-Term Investments	151.47K	66.08K	818.16K	1.41M	1.34M	306.51K
Total Debt	11.27K	11.44K	12.80K	1.34M	1.44M	1.49M
Total Liabilities	395.46K	545.61K	470.72K	1.89M	2.16M	3.38M
Stockholders Equity	942.86K	834.81K	1.95M	1.47M	1.43M	3.89M
Cash Flow
Free Cash Flow	-1.38M	-796.85K	-1.35M	-1.47M	-1.73M	-3.00M
Operating Cash Flow	-1.38M	-796.85K	-1.33M	-1.47M	-1.68M	-2.39M
Investing Cash Flow	-3.76K	9.00K	382.92K	101.94K	-48.77K	-611.04K
Financing Cash Flow	1.05M	-1.95K	539.10K	1.35M	2.77M	783.92K

Blueberries Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.13 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHB	56 Neutral	C$9.07M	-7.47	-17.81%	―	13.01%	-2445.45%
BBM	52 Neutral	C$9.90M	―	-125.85%	―	52.39%	5.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	45 Neutral	C$59.88M	-1.69	-24.60%	―	190.43%	71.05%
IMCC	42 Neutral	$6.72M	-2.36	-36.94%	―	2.17%	88.34%
CANB	41 Neutral	C$5.53M	80.00	―	―	-8.84%	-96.82%